Review
Jul 2026
CDK4/6-Based Drug Research and Development: A Four-Year Update.
In-depth understanding of CDK4/6 inhibitors and the continuous development of bifunctional agents and protein degraders provides key theoretical and technical support for the design of next-generation therapeutic strategies to address current clinical limitations.
Miao-Xia Pu, Wenbo Xu, Li Ding et al.
· Anti-Cancer Agents in Medici... · 0 citations